INDEXING
TERMS:
drug monitoring #{149} nonsteroidal antiinflammatory drugs Ibuprofen, a propionic acid derivative, is an orally administered, nonsteroidal antiinflammatory agent. It is rapidly absorbed after oral administration (45 to 90 mm), is extensively bound to plasma proteins (99%), and has a relatively short elimination half-life (55 to 150 mm) [1] . Ibuprofen is metabolized by oxidation in the liver to produce two major metabolites:
2-hydroxy-and 2-carboxy-ibuprofen.
The conjugated and the unconjugated forms of these metabolites, as well as up to 10% of ibuprofen, are excreted in urine [2] . Ibuprofen appears to exert its pharmacologic actions by inhibiting cyclooxygenase and thus blocking the first step in the synthesis of prostaglandins [3] . Furthermore, high concentrations of ibuprofen inhibit the migration, adherence, swelling, and aggregation of neutrophils and the release of lysosomal enzymes [4] [5] [6] [7] . High doses of ibuprofen, received consistently for 4 years, significantly slowed the decline of pulmonary function in patients with cystic fibrosis and mild lung disease [8] . For ibuprofen to achieve the desired inhibitory effect on neutrophil activation and migration, peak plasma concentration (Cm,) of 50 to 100 mg/L had to be reached. 4 Preliminary data suggest that with very low ibuprofen concentrations, the opposite response may occur and the influx of neutrophils increase [9] . We determined the appropriate dose individually by pharmacokinetic analysis [8, 10] . Several methods to determine ibuprofen with HPLC or gas chromatography-mass spectrometry have been previously described [11] [12] [13] [14] . The assays used relatively large plasma sample volumes (up to 2 mL) and either multiple-step liquid or solid-phase extraction procedures. In this report, we describe the development of a reversedphase HPLC assay, requiring a small sample volume of only 50 tL and utilizing a single-step extraction and a chromatographic separation of 4.5 mm, to determine plasma ibuprofen concentration. This assay was then used to determine the pharmacokinetics of ibuprofen in patients with cystic fibrosis. Alto, CA). Then 20 .tL of the supernatantisinjectedinto the HPLC. The chromatographic separationisperformed at ambient temperature with a flow rate of 1.5 mL/min and monitored at 220 nm. The colunm back pressure is 50 kg/cm2 and the absorbance unit fullscaleof the detectoris0.1.
Materials and Methods

REAGENTS
PHARMACOKINETICS
AND DOSE DETERMINATIONS
Cysticfibrosis patients (6 males and 14 females;ages 1-42 years, mean ± 1SD of 11.5 ± 9.1years;weight 10-63 kg,mean ± SD of 33.6 ± 14.7 kg) were given ibuprofen,3 h afterbreakfast, at an initial dose of 25 mg per kg of body weight to a maximum of 1600 mg, as previouslyreported [8, 10] . Sixteen patientstook ibuprofen in the form of tabletsand 4 in the form of elixir (Motrin;Upjohn). Thirteen of thosereceivingibuprofentablets used Motrin. The remaining 3 used different brand names of ibuprofen tablets. We obtained heparinizedplasma specimens before,and every 30 mm after, the administrationof the drug for up to 4 h. The dose thatachieved Cm*x of 50 to 100 mg/L was considered the patient's appropriatedose. In two patients, Cm*x exceeded the targetconcentration.Therefore, the pharmacokineticstudywas repeatedwith a smalleribuprofendosage thatwas changed to Motrin brand.
PHARMACOKINETIC CALCULATION
The first-order eliminationrateconstant(Ke) foribuprofenwas determined from the slopeof the linearregressionanalysis of a plot of time (x-axis) vs the naturallog of ibuprofen concentration(y-axis). The correlation coefficient observed between time and log ibuprofenconcentrationduring the terminalelimination phase in these20 patients ranged from 0.907 to 1.00with a mean (±SD) of 0.982 (±0.02).Ke was then used to extrapolatethe (Cl/F, mL/min per kg, where F is the bioavailability factor), and the volume of distribution (Vd/F, mL/kg) were calculated aspreviously described [16] . The bioavailability factor for ibuprofen ranges from 93% to 100% (Upjohn, personal communication). 
Results and Discussion
The absolute retention time of the internalstandard and ibuprofen were 2.6 and 3.9 mm, respectively. A typicalchromatogram of an extractedpatientspecimen containingibuprofen (75 mg/L) and the internal calibration ispresentedin Fig.1 .
Initially, we experiencedsome difficulty obtainingibufenacand, therefore, used 5-(p-methylphenyl)-5-phenylhydantoin (MPPH) (Sigma) as an internalstandard.However, a longer column (10 cm) had to be used to adequatelyseparateMPPH from the solventfront,resulting in a longer separationtime (7 mm). Furthermore, the variations seen in the performance of the assay were greater than when ibufenac was used as the internalstandard.
The calibration curve (Fig. 2) , with ibuprofenconcentrations of 25-150 mg/L, was shown to be linearbased on seven replicate measurements at the threeconcentrations[mean residual values (predicted-observed concentration)± SD for the concentrationsof25,75,and 150 mg/Lwere -0.11 ± 0.92, 0.18 ± 1.53, and 0.07 ± 0.61 mg/L, respectively] and reproducible(average CVs for the calibrators = 1.8% for n = 21).We determined a run-to-run precision,reflectedby CV, on 23 replicatesof quality-control materialswith two differentdrug concentrations. We evaluated each set of controls with a newly established calibration curve.For drug concentrationsof 50 and 100 mgfL, the precisionwas 3.0% and 2.8%, respectively. Recovery study was performed aftersupplementing four different ibuprofenfreeplasma samples with known amounts of purified ibuprofen.
At ibuprofen concentrationsof 25, 50, 100, and 150 mg/L, the assay displayedrecoveriesof 95, 96, 101, and 100%, respectively. Furthermore, the assay was shown to be sensitive down to 1 mg/L with reproducibility of 5.2% (n = 5) at that concentration and linear up to 500 mg/L. These limits of analytical range more than encompass the expected range of ibuprofen concentrations encountered in determining the appropriate dosage in the cystic fibrosis population (5-12 5 mgfL).
To further confirm the accuracyof this assay, we conducted an interference study with 51 commonly prescribedand some over-the-counter medications (Table 1) . These drugs were testedat theirtoxicconcentrations. We testedfor medications, particularly antibiotics, that are often used by this study population. Of the drugs tested, only two were able to be extracted Each point represents the mean at that particular time point; each bar represents 1 SD.
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and detectedwith thisassay:Ketoprofen and dicloxacillin eluted with retentiontimes of 1.1 and 1.74 mm, respectively. These retentiontimes are different from those of ibuprofen (3.9mm) and the internalstandard(2.6mm). This assaycan be assumed to be free of interferencefrom severalhundred other drugs because these drugs would eithernot be coextractedunder the conditions reported here, or they would have significantly different retentiontimes,or they would be used therapeutically at concentrations that are several magnitudes lower than ibuprofen.
We conducted a stability study to determine the adequate short-term storage conditionswith patientsamples for a wide range of ibuprofen concentrations(2-114 mgfL). Heparinized samples were analyzed immediately aftercollectionand after storageforup to 18 days at4#{176}C, up to 53 days at -20 #{176}C, or up to 53 days at -70 #{176}C. Our dataindicate no significant difference in ibuprofen concentration in samples stored refrigerated (mean ± SD, 49.5 ± 28.5 vs 49.2 ± 28.1 mg/L; P <0.9; mean differences ± SD, 0.28 ± 0.94 mg/L; n = 8) or frozen ateither -20#{176}C (45.8 ± 44.5 vs 45.0 ± 44.1 mgfL; P <0.9; mean differences ± SD, 0.64 ± 1.61mg/L; n = 6) or -70 #{176}C (47.9 ± 37.1 vs 46.0 ± 36.8 mg/L; P <0.9; mean differences± SD, 1.98 ± 1.67 mg/L; n = 6).
Our assay was compared with that of Minkler and Hoppel [11] , used in the recentlyreported study of the effectof high dose of ibuprofen in patientswith cysticfibrosis [8] . We analyzed simultaneouslyby both methods 42 plasma samples with a wide range of ibuprofen concentrations(7-114 mg/L). No differencewas seen in ibuprofen valuesdetermined by the two assays(mean ± SD of 48.2 ± 29.1 vs 47.9 ± 27.8 mg/L, P <0.5). A linearregressionanalysisshowed that the two chromatographic methods correlated very highly(r = 0.99)and gave a slope of 0.96 and an interceptof 0.16 mg/L. The standard errorsof the estimate,slope,and interceptare 2.369, 0.0186, and 0.876,respectively.
We performed pharmacokineticstudieson 16 patientsgiven ibuprofen tablets and on 4 patientsgiven ibuprofen syrup.The pharmacokineticsof the two groups are listed in Table 2 . The C,,.,0,, occurred between 60 and 120 mm in 15 of the 16 patients given ibuprofen tabletsand after30 mm in patientsreceiving ibuprofen syrup (Fig. 3) . Two of the 16 patientsreceiving ibuprofen tabletshad to have their pharmacokinetic studies repeatedbecause theirCm,,, exceeded the acceptableconcentration of 100 mg/L. In these two subjects, a shorter observed time to the peak concentration(Tm,,,,) was seen when the dose was reduced (Fig.4) .In patient"A" (weight 63 kg),the apparent Tmax was 180 mm at 1600 mg of ibuprofen and 60 mm at 1400 mg. In patient"B" (weight47 kg),the Tm,,,, was iso mm at 1200 mg of ibuprofen and 90 mm at 1000 mg. Besides the lowered dose, both patientswere also changed to Motrmn brand from other brands they used with theirhigher dose.When thesedata were combined with the present 16 pharmacokineticstudies, we observed a correlationbetween the absolutedose of ibuprofen (in mg) and the Tm,,,, (r = 0.594, P <0.05, n = 18). No significant correlationwas noted between ibuprofen dose and C,nax (r = -0.15). Although we have not systematically studied the kinetics of brands other than Motrin, the two casesthathad higherand delayed Cm,,,, were on otherbrands.We areunable to separate the effectof lowering the dose from changing to Motrin in bringingthe pharmacokineticsto the expectedrange.
Further studiesare needed to illustrate the effectof different brands of ibuprofen on the pharmacokinetics.
According to current nationalguidelines, four blood specimens, one before and three after the administration of ibuprofen tabletsat time intervals of 60, 120, and 180 mm, should be collectedto adequately determine Cmax [17] . If thisguideline had been followed, 3 of our 16 patientswould have given inconclusivepatternsand had to have theirpharmacokinetic studiesrepeatedwith additional blood specimens obtainedafter 90 and 150 mm of the administration of ibuprofen. However, two of these subjectshad to have theirpharmacokinetic study repeatedbecause theirC,,,,,,, at 180 mm exceeded 100 mgfL. No such national guidelinesare availableregarding the use of ibuprofensyrup inyoung patients. Our limiteddataindicate that three blood specimens in these patients, one before and at 30 and 60 mm after the administration of the ibuprofen syrup, are adequate to establish Cma,, (Fig. 3 ).
In conclusion,the assay reported here is simple, quick (time for extraction of -3 mm and chromatographic separation of 4.5 mm), precise, and requires small plasma sample volume of 50 .tL. Sampling and time intervals to establish ibuprofen Cm,,,, depend on whether the patient is administered tablets or syrup. Our assay is ideallysuited to conducting pharmacokinetic studies to determine the adequate ibuprofen dose for pediatric cystic fibrosis patients.
